European CHMP recommends approval of biosimilar of bevacizumab (Aybintio) 25 mg/ml concentrate for solution for infusion

Bevacizumab, a monoclonal antibody which binds to vascular endothelial growth factor, thereby inhibiting tumour growth is licensed for treatment of colon, rectal, breast, and non-small cell lung, renal and ovarian cancers.


European Medicines Agency